Kowal Investment Group’s Axsome Therapeutics AXSM Stock Holding History

Kowal Investment Group’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-14	Closed	–	–	192
2021 Q3	$0	Buy	+14	New	+$546	﹤0.01%	915

Other funds holding AXSM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

ACM

Alethea Capital Management Mercer Island, Washington $195M AUM 51.17% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Kowal Investment Group's AXSM Position: Q4 2021 in Review

Kowal Investment Group sold out of Axsome Therapeutics (AXSM) in Q4 2021, closing a stake of 14 shares.

Kowal Investment Group first reported a position in AXSM in Q3 2021 and held it in 1 quarter. The position peaked at $0 in Q3 2021. 167 funds tracked by Wall St. Rank hold AXSM as of Q4 2021.

Kowal Investment Group reported no remaining Axsome Therapeutics position as of Q4 2021 after selling out during the quarter.
Kowal Investment Group sold 14 Axsome Therapeutics shares in Q4 2021.
Kowal Investment Group first reported a position in Axsome Therapeutics in Q3 2021 and held it in 1 quarter.
Kowal Investment Group's Axsome Therapeutics position peaked at $0 in Q3 2021.
167 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q4 2021.

Based on Kowal Investment Group's 13F filing for Q4 2021, filed 11 Feb 2022.